the dam has broke and I was floated down stream to another pond. Grab a hold of Kitty's raft if you can. $5.80 could be bottom. At $5.80 a low ball offer would be a welcome by disillusioned shareholders. Wouldn't it be funny that TSRX gets bought out by Bayer for a large bottle of aspirin. NOT!
Wall St never fails to deliver.
Ships, I replied earlier with a lengthy post and it was deleted by Yahoo. To make a long postr much shorter TSRX is a great longterm hold and buy on dips.. What analysts and biotech journalists don't get is that the projec ted 300 million dollar a year revenue stream for Tedizolid is ridiculous. Here's why...Tedizolid's trial design was for "non inferiority". Given once a day for MRSA skin infections it performed slightly better than the standard-of-care, Linezolid. In the trial Linezolid was administered twice a day for 7 days, Ted 5 days. Ted chemically is a more potent compound. Once this drug is approved Infectious Disease MD's will review the trial data and conclude like I have that Ted. is more potent. Once approved MD';s will gravitate towards Tedizolid because of this data. Off-label use will result in TSRX crushing all projected revenue totals. This drug in 2 years will hit 1 billion. If and when Trius conducts a small "superiority" trial Vs. Linezolid by administering the same dose twice a day for 7 days it will prove to be superior to the doc and it's off to the races. A year from now this stock, if not bought out by then, will be north of $20 pps and will be one of the darlings of biotech. TSRX receives a nice "milestone payment" from Bayer [asia partner] for filing an NDA and upon FDA approval of Tedizolid. This company gets bought out above $50 ops within the next 18 months.
Sentiment: Strong Buy